Prescribing Ziprasidone

At a glance

The metabolically clean atypical for patients who must avoid weight, glucose, lipid and prolactin effects; needs food every dose and a QT eye.

How to doseFull section

Comes as

Capsule20, 40, 60, 80 mg

Injection (IM)single-dose vial; 20 mg ziprasidone/mL when reconstituted

Example photos; looks vary by maker. Click to enlarge.

In shortTake every dose with food, twice daily; the label starts at 20 mg for schizophrenia or 40 mg for mania and tops out at 80 mg twice daily, while practice starts schizophrenia at 40 mg.

FDA labelIn practice

A row across both columns means the label and usual practice agree. Off-label marks the few places where practice goes beyond what the label allows.

Adultsschizophrenia

StartFDA label20 mg twice daily with foodIn practice40 mg twice daily with food.

IncreaseFDA labelIn some patients, if indicated, adjust generally at intervals of at least 2 days; ordinarily observe for several weeks before upward adjustment.In practiceOff-labelUsually titrate to 80 mg twice daily within 1–2 days, as tolerated.

TargetFDA labelEfficacy shown at 20 to 100 mg twice daily in short-term, placebo-controlled trials.In practice80 mg twice daily (160 mg a day), the dose that separated from placebo in trials.

MaximumFDA labelUp to 80 mg twice daily. Going above 80 mg twice daily is not generally recommended.In practiceOff-label160–320 mg a day is used when 160 mg fails, with little trial support. Above 160 mg a day, get an ECG and document the reasoning.

Adultsbipolar I, manic or mixed episodes

StartFDA label40 mg twice daily with food

IncreaseFDA labelMay increase to 60 or 80 mg twice daily on the second day, then adjust by tolerance and efficacy within 40 to 80 mg twice daily.In practiceTitrate fast to 80 mg twice daily within 1–2 days, as tolerated.

TargetFDA labelIn flexible-dose trials, the mean daily dose was about 120 mg.In practiceAbout 120 mg a day (mean optimal about 119 mg a day in flexible-dose trials).

MaximumFDA labelTop of the range is 80 mg twice daily (range 40 to 80 mg twice daily).In practiceOff-label160–320 mg a day is used when 160 mg fails, with little trial support. Above 160 mg a day, get an ECG and document the reasoning.

MaintenanceFDA labelAdjunct to lithium or valproate: continue the dose that stabilized the patient, within 40 to 80 mg twice daily with food.

IM for acute agitation (schizophrenia)FDA label10 to 20 mg IM as required, up to 40 mg a day. 10 mg may be given every two hours; 20 mg every four hours.In practiceGo with 20 mg unless there is a reason not to. Do not reflexively drop to 10 mg out of QT anxiety; the label still flags its greater QT effect.

Older adultsFDA labelSome elderly patients with several factors that might raise response or cause poorer tolerance or orthostasis: consider lower start, slower titration.In practiceAging slows clearance: start lower, titrate more slowly, and don't assume adult target doses.

Kidney or liver impairmentFDA labelKidney: no dose adjustment for the degree of impairment. Liver: AUC would be expected to increase.In practiceOral: no kidney change. IM: the vehicle is renally cleared, so use IM cautiously. Liver: use caution, levels can rise.

How to take itFDA labelOral capsules with food, swallowed whole. Twice daily.In practiceFood with every dose, no exceptions; a meal roughly doubles absorption. Twice daily: half-life about 7 hours.

Stopping and switchingFDA labelPsychiatric MAOI: at least 14 days after stopping it before starting ziprasidone; 3 days after stopping ziprasidone before starting it.In practiceNo drug-specific schedule: cut about 25–50% every 1–4 weeks, slower near the end; a stable long-term patient should taper over months, not weeks.

IndicationsFull section

FDA-approved

Schizophrenia, acute and maintenance (oral)

Acute agitation in schizophrenia (IM)

Bipolar I acute manic or mixed episodes (mono or adjunct)

Off-label, evidence-based

Depression augmentation, 20–40 mg qAM (thin RCT data)

Boxed warningsFull section

Dementia-related psychosis mortality, elderlyRR ~1.6–1.7; not approved; off-label only with consent, lowest dose, shortest duration

ContraindicationsFull section

Known QT prolongation, incl. congenital long-QTContraindicated (label); pick another agent

Recent acute MIContraindicated (label)

Uncompensated heart failureContraindicated (label)

Named QT-prolonging drugs (label list)Also any drug with its own QT contraindication or boxed or bolded QT warning

History of significant arrhythmiaLabel says avoid; aripiprazole instead, or ECGs only if nothing else fits

MonitorFull section

Weight, BMI, waistBaseline, ~6 mo, then yearly

Glucose/A1c, lipidsBaseline, ~4 mo, then yearly (some do lipids every 2 yr)

ECGBaseline if cardiac disease or ≥65; repeat above 160 mg/day or with cardiac symptoms. No QT co-meds

K, MgIf cardiac risk, diuretic or purging history; correct before and during

AkathisiaAsk at every early visit

AIMSPeriodically; TD ~3.5%/yr pooled (Carbon 2018), vs 2.6% SGA, 6.5% FGA

Cognition, orthostasisElderly: orthostasis early, cognition periodically

No routine ECG in low-risk patients.

Drug interactionsFull section

Drug-drug

Trazodone, methadoneThe QT stacking met most; label says not to prescribe together: stop or replace one

Class IA/III antiarrhythmics, antipsychoticsAdditive QT prolongation; label contraindicates or advises against; stop or replace one

Macrolides, fluoroquinolones, antifungalsAdditive QT prolongation (higher-dose ondansetron too); stop or replace one

Carbamazepine, phenytoin, rifampinLower levels (carbamazepine 200 mg bid cut AUC ~35%); watch for loss of effect

KetoconazoleRaised AUC and Cmax ~35 to 40% (400 mg daily); not contraindicated

CYP enzymes

CYP oxidationSubstrate, under one-third of clearanceKetoconazole raises AUC ~35–40%; carbamazepine lowers it ~35%

Aldehyde oxid.Two-thirds of clearance (reduction)No known clinically relevant inhibitors or inducers

CYP1A2Not a substrateSmoking does not change levels; no dose change on admission or quitting

Not heavily CYP-dependent; unlike lurasidone, not contraindicated with ketoconazole or rifampin.

Must counselFull section

Take with mealsEvery dose with a real meal, or it won't work well

Restless or wiredCan happen in week 1; call me if it's bad, we can adjust

SleepinessMild and early; usually gone after 1–2 weeks

NauseaTaking it with food helps

Stiffness, tremorTell me; a lower dose or a short-term med helps

Fainting, racing heartCall right away; we may check an ECG

StoppingDon't stop suddenly; we taper to avoid rebound

PearlsFull section

Food is the efficacy rule: a meal doubles absorption, and fasting doses look like the drug stopped working. If they won't eat with it, pick another.

QT is real but overblown: ~10 msec at 160 mg/day oral; IM matches haloperidol. ECG for cardiac history, ≥65, high dose or symptoms. QT-drug combos: stop or replace one.

IM 20 mg calms without sedating, so the patient stays interviewable; don't undershoot to 10 mg out of QT fear.

Akathisia (~13%) is the usual dealbreaker: lower dose, propranolol, clonazepam bridge, mirtazapine 15 mg; never benztropine.

CYP-clean and smoking-proof: carbamazepine cuts AUC ~35%, ketoconazole raises it ~35–40%. Trazodone and methadone are the QT stacking you will meet most: avoid.

Fails in treatment-resistant schizophrenia? Go to clozapine; don't stall.

Summary of this guide. Check the full sections before prescribing.

Photo credits

Ziprasidone 40 mg capsules, box and blister: Rkjon, CC BY-SA 4.0, Wikimedia Commons

Ziprasidone 60 mg, box: Rkjon, CC BY-SA 4.0, Wikimedia Commons

Why Ziprasidone Still Matters

Ziprasidone is the second-generation antipsychotic you prescribe when you have decided that weight gain, diabetes, and dyslipidemia are the risks you most want to avoid. With aripiprazole, brexpiprazole, lumateperone, and lurasidone, it belongs to the small club of metabolically clean atypicals: in mania trials patients gain roughly 1.1 kg, glucose and lipids don't budge from placebo, and prolactin stays flat. For a patient who is already obese, prediabetic, dyslipidemic, or simply young and appearance-conscious, that profile is worth a great deal.

Two burdens keep it from being a default first-line agent, and you need to understand both to use it well. The first is the food requirement: ziprasidone's absorption roughly doubles when taken with a meal, so a patient who swallows it on an empty stomach gets roughly half the intended exposure. The second is QTc prolongation. The liability exists, but it has been badly overblown, and it has scared a generation of prescribers away from a good drug.

A third caveat shapes how you counsel patients: the early side-effect response to ziprasidone is unpredictable. Some patients get sedated at 20 mg BID, others feel wired and akathisic on the same dose, and many feel nothing unusual at all. You cannot forecast which patient you have. That is no reason to avoid the drug, but it is a reason to warn the patient up front, so the first week doesn't sour them on it.

Part 1: Indications

FDA-Approved Uses

• Schizophrenia (acute and maintenance), oral
• Acute agitation in schizophrenia, intramuscular (IM)
• Acute manic or mixed episodes of bipolar I disorder, oral (as monotherapy or adjunct)

The Evidence-Based Clinical Uses

Schizophrenia, the core indication. Efficacy is squarely in line with the rest of the class. In the CATIE effectiveness trial, ziprasidone came out metabolically clean and safe for the heart despite all the QT concern. It showed no efficacy superiority but had the lowest weight gain of the agents studied. In a meta-analysis of 76 trials (13,558 patients), olanzapine and risperidone edged it out on symptom scales, but the gap was clinically small (roughly 16 patients needed to treat to realize olanzapine's advantage in avoiding dropout for inefficacy). Practically, ziprasidone is a fully adequate antipsychotic that you choose for tolerability, not potency.

Acute mania. FDA-approved and clearly effective. The mean optimal dose in flexible-dose trials was ~119 mg/day, and efficacy is comparable to other atypicals (risperidone and olanzapine run slightly ahead on raw efficacy, olanzapine most of all).

Acute agitation (IM), an underused strength. The injection does something the oral formulation doesn't: IM ziprasidone calms without flattening. Patients settle but stay awake and workable, unlike the sledgehammer sedation of IM haloperidol or lorazepam. Reconstitution needs only sterile water and a 30-second shake, faster than competitors. For an emergency psychiatrist who wants to de-escalate and still interview the patient, that is a clear advantage.

Depression augmentation, off-label, real-world use. Some clinicians add 20–40 mg in the morning to an antidepressant in resistant unipolar depression, because it is metabolically clean. The RCT evidence is thin; treat this as a reasonable, monitored off-label option rather than an established one.

Where Ziprasidone Does Not Belong

• Bipolar depression: limited RCT data; not FDA-approved. Quetiapine, lurasidone, cariprazine, and lumateperone have real evidence here; reach for those instead.
• Borderline personality disorder: a 12-week RCT (N=60, mean 84.1 mg/day) showed no benefit over placebo. Don't use it for BPD.
• Treatment-resistant schizophrenia: no advantage. If ziprasidone fails after an adequate trial, move to clozapine, don't stall. Clozapine is the only atypical clearly superior in TRS.

The Ideal Ziprasidone Candidate

Screen for ziprasidone when:

• Metabolic risk is the dominant concern: obesity, diabetes, dyslipidemia, or a patient who cannot afford further weight gain
• Prolactin-related problems matter: galactorrhea, amenorrhea, or sexual dysfunction on a prior agent (ziprasidone doesn't raise prolactin)
• The patient smokes: ziprasidone levels are unaffected by smoking status (it's not a CYP1A2 substrate), unlike clozapine and olanzapine
• The patient reliably eats with their doses; this is non-negotiable

Screen against it when the patient has real cardiac disease, an unstable QTc, uncorrected hypokalemia/hypomagnesemia, or a lifestyle that makes eating with doses unrealistic.

Part 2: Before You Start: Workup and Candidacy

Ziprasidone's baseline workup is lighter than lithium's or clozapine's, but two things deserve attention: metabolic parameters (as a baseline, even though this drug rarely moves them) and cardiac risk.

Baseline Labs and Studies

For this drug the metabolic labs are close to a formality. You don't expect ziprasidone to derange them; you draw them to have a baseline. Drawing them anyway keeps you honest and gives you a reference if you ever switch agents.

The ECG Question: Follow the FDA, Don't Over-Order

You do not need a baseline ECG in a young, healthy patient with no cardiac history. This is one of the most over-ordered tests in psychiatry.

Who Is a Poor Candidate?

• Recent acute MI or uncompensated heart failure: contraindicated (label). Other known cardiac disease or a history of significant arrhythmia: avoid (the label says to avoid ziprasidone with a history of cardiac arrhythmias); choose aripiprazole instead, or use it only with baseline and follow-up ECG if no alternative fits
• Known QT prolongation (including congenital long-QT syndrome) or a QT-prolonging drug that can't be stopped: contraindicated (label); pick another agent
• Uncorrected hypokalemia or hypomagnesemia: correct first
• A patient who cannot or will not eat with doses: the food requirement makes ziprasidone the wrong drug for the chaotically nonadherent or the person who skips meals

Part 3: How to Start and Dose

Formulations

• Oral capsules: 20, 40, 60, 80 mg
• IM (ziprasidone mesylate): for acute agitation; reconstitute with sterile water, shake ~30 seconds

Off-label high dosing. Some clinicians and pharmacists push ziprasidone to 160–320 mg/day when 160 mg fails, reasoning that food-and-absorption variability leaves many patients underexposed at standard doses. This is off-label and has little trial support. If you go above 160 mg/day, get an ECG and document your reasoning. Super-dosing is exactly when the ECG earns its keep.

The Food Rule

No counseling point matters more than this one. Ziprasidone must be taken with food, every dose, no exceptions. A meal roughly doubles bioavailability; on an empty stomach absorption falls to about half of that. A patient who takes it fasting isn't getting a low dose; they're getting an erratic one, and the drug will look like it stopped working. Anchor it to breakfast and dinner. Make this the first thing you say and the last thing you write on the after-visit summary.

The Unpredictability Warning: Build It Into Consent

Tell the patient this at the start: "For the first week, you might feel a little sedated, or you might feel a little restless and wired. Either usually settles. Call me if it's bad, we can adjust." That five-second script keeps the patient from quitting on day three and calling it a failure.

Dose Adjustments and Special Populations

• QTc (the defining caution): ziprasidone prolongs QTc more than most atypicals. It is contraindicated in patients with known QT prolongation, recent acute MI, or uncompensated heart failure, and should not be combined with other QT-prolonging drugs. Correct hypokalemia/hypomagnesemia before and during treatment; get a baseline ECG and electrolytes in at-risk patients and any time you exceed 160 mg/day off-label.
• Pediatric: not FDA-approved.

Stopping and Switching

• Discontinuation: taper to reduce rebound; recheck an ECG when switching to another QT-prolonging agent.

Part 4: Monitoring

Ziprasidone is a low-metabolic-risk ("clean") agent, so its monitoring cadence is lighter than an olanzapine or clozapine patient's.

Metabolic Monitoring

For a clean agent, annual metabolic labs after the first check suffice. You don't need the monthly-then-quarterly vigilance a "dirty" agent demands.

Cardiac / QT Monitoring

• No routine ECG in low-risk patients.
• Repeat ECG if you push the dose above 160 mg/day or if cardiac symptoms develop. Do not add a QT-prolonging co-medication: the label contraindicates or advises against it (see QT-Prolonging Co-Medications).
• Know the actual numbers so the fear stays proportional: oral ziprasidone lengthened QTc by about 10 msec against placebo at 160 mg/day, the highest recommended dose. Given intramuscularly, the mean rise was 4.6 msec after the first injection and 12.8 msec after the second, against 6.0 and 14.7 msec for IM haloperidol. Torsades was not observed in premarketing studies, and post-marketing reports are rare and confounded.

Movement and Clinical Monitoring

• Ask about akathisia (inner restlessness) at every early visit; it's the most common and most under-recognized reason patients quit.
• Screen periodically for EPS and tardive dyskinesia (an AIMS exam on a reasonable interval); TD risk is lower than with typical antipsychotics but not zero (second-generation antipsychotics about 2.6%/year against 6.5% for first-generation in head-to-head trials, Carbon 2018; about 3.5%/year for ziprasidone in that analysis, a non-randomized pooled estimate with a wide interval).
• In the elderly, monitor cognition (atypicals can nudge MMSE down) and watch for early orthostasis.

Part 5: Side Effects and How to Manage Them

As with the rest of the class, ziprasidone's dangerous side effects are rare, its metabolic side effects are minimal, and its bothersome side effects are movement-related and early. Manage akathisia aggressively; it's the usual dealbreaker.

Movement Disorders: The Main Liability

Akathisia. The characteristic nuisance of ziprasidone: ~13% vs 3% on placebo, dose-related, and more than several comparators. It is distressing, it wrecks adherence, and when severe it is linked to increased suicide risk.

Management (stepped):

1. Lower the dose if clinically feasible; akathisia is dose-related.
2. Propranolol 20 mg IR two to three times daily; titrate to effect and pulse (check pulse before doses, hold if <60; some patients need up to ~240 mg/day). Switch to a long-acting formulation once the effective dose is found. This is first-line.
3. Benzodiazepine bridge for rapid relief while propranolol is titrated: clonazepam 0.5 mg BID standing + 0.5 mg q6h PRN.
4. Mirtazapine 15 mg QHS as a second-line option. The randomized trial supporting it used 15 mg against propranolol 80 mg and placebo, so keep it there.
5. If akathisia is refractory, switch antipsychotics. Aripiprazole is a poor choice for this particular problem: its own akathisia rates were 8% against 4% on placebo in adult schizophrenia trials and 13% against 4% in bipolar mania monotherapy.

Do NOT reach for benztropine/anticholinergics for akathisia: they don't treat it (they treat parkinsonism only).

Parkinsonism / EPS. ~27% in longer studies, dose-dependent, comparable to risperidone and olanzapine. Management: reduce dose, or benztropine 0.5–2 mg BID for parkinsonian rigidity/tremor. Try to deprescribe the anticholinergic after 6–8 months; the ongoing dry-mouth/cognitive cost is too high to carry indefinitely.

Dystonia. More likely early and at higher doses. Acute dystonia responds to benztropine 2 mg IM/IV, usually resolving within 5–30 minutes.

Tardive dyskinesia. About 3.5%/year for ziprasidone in a pooled analysis (Carbon 2018; non-randomized, wide interval), against 2.6% for second-generation antipsychotics overall and 6.5% for first-generation. Screen with periodic AIMS exams, especially in older and long-treated patients.

Metabolic

• Weight: ~1.1 kg in mania trials; minimal overall. Among the cleanest agents.
• Glucose: no significant rise vs placebo.
• Lipids/triglycerides: no significant rise vs placebo.
• Prolactin: not elevated; no galactorrhea, amenorrhea, or prolactin-driven sexual dysfunction.

This profile is the reason to choose ziprasidone. If a patient does gain weight or shows glucose creep, look hard for another cause before blaming the drug.

Sedation: Mild and Usually Transient

Mild-to-moderate early, and virtually gone later in treatment, far less than quetiapine, though a bit more than aripiprazole. If early sedation is a problem, load more of the dose in the evening. It typically accommodates within 1–2 weeks. (Remember the unpredictability caveat: some patients feel activated rather than sedated.)

Nausea: Common

10% vs 7% placebo in both the schizophrenia and the bipolar mania trials. Taking it with food, which the patient must do anyway, mitigates it on its own. Ginger or a short course of an antiemetic covers the rest.

Cardiac / QT

Covered in Monitoring. The clinical bottom line: about 10 msec of QTc prolongation at 160 mg/day, torsades not seen in premarketing studies, and post-marketing reports that are rare and confounded. Manage by respecting electrolytes, avoiding stacked QT-prolongers, and getting an ECG when you go high-dose or the patient has cardiac risk, not by avoiding the drug.

Orthostatic Hypotension / Dizziness

Minimal, less than iloperidone. Mild alpha-1 antagonism is the mechanism. Counsel to rise slowly and stay hydrated; rarely an issue.

Other

• Headache, asthenia/fatigue: reported, generally mild and dose-related.
• Sexual dysfunction: not prominent, because there's no prolactin elevation and minimal anticholinergic burden. A selling point over risperidone.

Part 6: Overdose, Toxicity, and Boxed Warnings

Two more class-wide risks apply, though ziprasidone carries no elevated liability for either relative to the rest of the class:

• Neuroleptic malignant syndrome (NMS): rare, life-threatening: fever, rigidity, altered mental status, autonomic instability. Stop the drug; supportive care, cooling; dantrolene/bromocriptine if severe.
• Tardive dyskinesia: as above, about 3.5%/year pooled (Carbon 2018).

Overdose

There is no specific ziprasidone overdose syndrome or antidote. Management is supportive: airway, continuous cardiac/QTc monitoring (the one organ-specific concern given the QT effect), correction of electrolytes, and treatment of seizures or NMS if they arise. Seizure risk is not elevated at therapeutic doses. The post-marketing safety record is reassuring: the theoretical torsades fear has not materialized into a body count.

Part 7: Drug Interactions

Pharmacokinetically, ziprasidone is refreshingly clean. Its interactions are almost entirely pharmacodynamic (QT stacking), not a matter of CYP metabolism.

QT-Prolonging Co-Medications

The interaction that actually matters is additive QT prolongation. The label contraindicates combining ziprasidone with a named list of QT-prolonging drugs and with any drug whose own label carries a contraindication or a boxed or bolded QT warning, and says to avoid it with other QT-prolonging drugs:

• Trazodone (common in psychiatry for sleep) and methadone are the two you'll meet most.
• Also: class IA/III antiarrhythmics, other antipsychotics, certain macrolides and fluoroquinolones, some antifungals, and higher-dose ondansetron.
• If you find the combination already in place: the label says not to prescribe them together, so stop or replace one of the two. Until then, get a baseline ECG if the patient is ≥65, has cardiovascular disease, has electrolyte abnormalities, or has hepatic/renal impairment, and recheck periodically. Correct low K⁺/Mg²⁺ first.

CYP450: Mostly a Non-Issue

• Ziprasidone is not heavily CYP-dependent. Less than one-third of its metabolic clearance runs through CYP450 oxidation; about two-thirds goes through reduction by glutathione and aldehyde oxidase, an enzyme with no known clinically relevant inhibitors or inducers.
• Unlike lurasidone, ziprasidone is not contraindicated with ketoconazole or rifampin, a real advantage when interaction risk is high. Ketoconazole 400 mg daily raised ziprasidone AUC and Cmax by about 35 to 40%.
• Strong CYP inducers (carbamazepine, and by extension phenytoin, rifampin) lower ziprasidone levels: carbamazepine 200 mg twice daily cut AUC by about 35%. Watch for loss of effect and adjust clinically.
• Smoking does not meaningfully affect levels (not a CYP1A2 substrate). Excellent for smokers: no dose change on admission or after quitting, unlike clozapine and olanzapine.

The Food "Interaction"

Not a drug interaction, but it belongs on every interaction checklist: food doubles absorption. An empty stomach is functionally a 50% dose reduction. See Part 3.

Part 8: Special Populations

Pregnancy

We have less data on ziprasidone than on the older atypicals. Risperidone, olanzapine, and quetiapine carry more reproductive safety data, and when an antipsychotic is clearly needed in pregnancy, those better-characterized agents are usually preferred. Teratogenic data for ziprasidone are minimal, and what exists is neither reassuring nor alarming, just sparse.

Practical stance: use ziprasidone in pregnancy only when the benefit clearly outweighs the risk and there's a specific reason to prefer it (for example, the patient is stable on it and switching risks relapse). Otherwise favor an agent with more pregnancy data. Discuss the data gap explicitly, and coordinate with obstetrics.

Lactation

Data are limited. Antipsychotics generally appear in breast milk in small amounts; ziprasidone is generally considered acceptable with monitoring of the infant for sedation and poor feeding, but the evidence base is thin, so individualize and coordinate with pediatrics.

Elderly (≥65)

• Aging slows clearance: start lower, titrate more slowly, and don't assume adult target doses.
• Get a baseline ECG: the combination of QT effect and the higher background prevalence of cardiac disease justifies it here even though you'd skip it in a healthy 30-year-old.
• Low anticholinergic burden is an advantage: ziprasidone is gentler on cognition and delirium risk than olanzapine or clozapine.
• Watch orthostasis and falls early; monitor cognition periodically.
• Remember the dementia boxed warning: off-label use in dementia-related agitation demands explicit informed consent and the lowest effective dose.

Renal and Hepatic Impairment

• No specific dose adjustment is mandated for either, and ziprasidone is not explicitly contraindicated in either. Less than 1% is excreted unchanged, so renal impairment alone is unlikely to shift the pharmacokinetics; the liver does the clearing, and cirrhosis raised AUC by 13% in Child-Pugh A and 34% in Child-Pugh B.
• Use caution and get a baseline ECG in significant hepatic or renal impairment: these states raise torsades risk (via electrolyte shifts and altered handling), which is the real concern, not accumulation per se.

Pediatrics

Limited data; generally not first-line in youth. If used at all, it's off-label with slow titration and close metabolic and cardiac attention. For most pediatric indications, better-studied agents exist.

Part 9: Discontinuation

Ziprasidone has no distinct withdrawal syndrome, but stopping any antipsychotic abruptly carries two real risks:

1. Rebound psychosis / mania from dopamine supersensitivity. Chronic D2 blockade upregulates D2 receptors; yank the drug and those hypersensitive receptors get flooded, and the rebound episode is often worse than the patient's baseline illness. Most post-discontinuation relapses are a blend of true relapse and this withdrawal/rebound phenomenon.
2. Withdrawal-emergent dyskinesia: choreiform movements, dystonia, akathisia appearing 1–4 weeks after an abrupt stop or fast reduction. Reinstate and taper slowly, or switch to a longer-acting strategy.

How to Stop

• Taper gradually: there's no ziprasidone-specific schedule, but a sensible approach is to reduce by ~25–50% every 1–4 weeks, going slower near the end of the taper where breakthrough is likeliest.
• For a stable chronic patient, taper over months, not weeks. A common cadence: halve the dose, then halve the remainder, repeating, individualized to the patient.
• Watch closely for relapse, especially in the first 1–6 months, and have a plan to resume promptly.
• Counsel the patient: staying on maintenance cuts relapse risk by about 40% versus stopping (in a bipolar maintenance meta-analysis, ~32% vs ~53% relapse at 6 months). Don't let a well patient talk themselves off it casually.

Part 10: Ziprasidone vs the Alternatives

Atypicals are roughly equally effective, so you choose by side-effect profile. The table shows where ziprasidone wins and loses head-to-head.

Ziprasidone is underused mostly because of its QT reputation: a modest, self-limiting ECG change got mythologized into a contraindication. Add the food requirement and the unpredictable early tolerability, and many prescribers reached for the marketed, once-daily, food-agnostic alternatives. None of that means the drug doesn't work. It means the drug asks a little more of you and the patient.

Mechanism

Ziprasidone is a mixed D2 / 5-HT2A antagonist, the defining pharmacology of the atypical class: D2 blockade in mesolimbic/mesocortical pathways quells psychosis, while 5-HT2A antagonism in nigrostriatal pathways preserves dopamine tone there, the trade that buys the class a lower tardive dyskinesia rate than typicals (about 2.6% against 6.5% a year in head-to-head trials, Carbon 2018). It adds mild alpha-1 antagonism (the source of its slight orthostatic effect) and has minimal H1 (antihistamine) and muscarinic (anticholinergic) activity, which is why it causes so little weight gain, sedation, and anticholinergic trouble. It also acts as an agonist at 5-HT1A and inhibits synaptic reuptake of serotonin and norepinephrine. Pharmacokinetically: half-life ~7 hours (hence BID dosing), peak ~6 hours, >99% protein-bound, cleared largely by hepatic metabolism (about two-thirds by glutathione and aldehyde oxidase, the rest by CYP450 oxidation) with renal/fecal excretion. Most important in practice, absorption doubles with food.

Bedside Cheat Sheet